Fig 1: Genetic profile–guided therapeutic approaches for ATR or RAD51 inhibitor treatment in BLCA. A Lollipop with distribution of ATR mutations (single nucleotide variants (SNV) comprising pathogenic mutations and variants of uncertain significance (VUS)), as observed in 1,527 samples (1,244 patients). Samples that had not been profiled for all genes of the following analyses in analyzed profiles were excluded from analysis (n = 132). UME domain (green, upstream regulatory region), FAT domain (red, FRAP–ATM–TRRAP), PI3/PI4 kinase catalytic domain (blue) and FATC domain (yellow). The presented number of ATR mutations (a overall 1,527; bputative pathogenic 18; cVUS 103) was adjusted by excluding duplicate mutations of patients with multiple samples (overall n = 19; i.e. n = 4 pathogenic and n = 15 VUS). B Wilcoxon test demonstrated a close link between TMB status and patients with genetic ATR alterations (altered) compared to those samples lacking mutations (unaltered) (p-value < 10− 10). C Intersection plot illustrating co-occurring mutations of ATR (orange), BRCA1 (blue), BRCA2 (pink), CHEK1 (green), and RAD51 (purple) in TCGA BLCA patient cohort. D Oncoprint showing only potentially pathogenic mutations of those five genes in all analyzed samples of the TCGA BLCA cohort (excluding n = 132 samples without information for all analyzed genes). Mutation types: missense (green), splice site (orange), truncating (black), structural variants (purple), deep deletions (blue), no alteration (grey). E Cartoon with hypothetical treatment strategies related to genetic alterations for ATR and RAD51 inhibitors. ATR wild-type (ATR WT): treatment with ATRi combined with ionizing radiation. ATRbypass (ATRi-resistant with HR repair activation): dual inhibition using ATRi and RAD51i. ATR-mutated (ATRmut): RAD51 inhibition. HRD (HR-deficient tumors): potential sensitivity to DNA damage response inhibitors. Overall frequency of patients harboring either ATRmut or HRD was 5.6% (70 out of 1,244 patients).
Fig 2: Pharmacological inhibition of ATR impeded DNA damage response after exposure to radiation. A-B Quantitative analysis of DNA double-strand break (DSB) repair via neutral comet assay. Patient-derived 2D cultures were exposed to 8 Gy of ionizing radiation (IR), ± ATRi (Ceralasertib, 1 µM). DNA damage was assessed by measuring tail moments at 0 h, 1 h, 3 h, and 6 h post-IR, calculated with ImageJ. At least 35 cells per condition were analyzed. (A) Top: tail moment for three p-SCC cell cultures (p-SCC1, p-SCC2, p-SCC3). Bottom: representative IF images of p-SCC comet tail (scale bar: 15 μm). (B) Same as in (A) for p-UC cell cultures (p-UC1, p-UC2, p-UC3). C-D Quantification of DNA repair through γH2AX foci analysis by IF microscopy. Patient-derived 2D cultures were exposed to 0, 2, or 8 Gy ± ATRi (Ceralasertib, 1 µM) pre-treatment followed by staining for γH2AX at 4 h and 24 h post-IR. Box plots quantify foci per nucleus calculated with ImageJ, with arrows showing a percent reduction in repair efficiency. At least 50 cells per condition were analyzed. (C) Top: γH2AX IF quantification as foci per cell in p-SCC. Bottom: representative IF images of γH2AX foci in p-SCC 4 h post-IR (scale bar: 20 μm). (D) Same as in (C) for p-UC cell cultures (p-UC1, p-UC2, p-UC3).
Fig 3: Exploring the radio-sensitizing potential of ATR inhibition in ex vivo BLCA cell models. A-D Short-term XTT cell viability assays were performed over 72 h to assess the effect of Ceralasertib (ATRi; 0.01–20 µM) in combination with ionizing radiation (IR; 0 Gy, 2 Gy, 8 Gy) in patient-derived 2D and 3D cultures. A Dose-response curves for three p-SCC cell cultures (p-SCC1, p-SCC2, p-SCC3). B Dose-response curves for three p-UC cell cultures (p-UC1, p-UC2, p-UC3). C Summary of IC50 values (µM) for all p-SCC and p-UC cell cultures across radiation doses. D Combined graphical representation of average dose–response behavior for all p-SCCs and p-UCs highlighting overall treatment responses. E Comparison of patient-derived 3D from p-SCCs and p-UCs exposed to ATRi without IR (0 Gy). F-G Long-term clonogenic survival assays were performed over 14 days and patient-derived 2D cultures were treated with ATRi (1 µM) and/or IR (0 Gy, 2 Gy, or 8 Gy). Top: calculated survival fractions for three p-SCC cell cultures (p-SCC1, p-SCC2, p-SCC3) or three p-UC cell cultures (p-UC1, p-UC2, p-UC3). Bottom: representative images of p-SCC or p-UC clonogenic formation
Fig 4: ATRi-adaptation reduced radio-sensitization and ATR–CHK1 pathway attenuation in patient-derived p-SCC models. A Schematic overview illustrating the generation of ATRi-adapted cell models. p-SCC1, p-SCC2, and p-SCC3 cells were continuously exposed to gradually increasing concentrations of ATRi (Ceralasertib) for over six months, resulting in adapted cell populations: p-SCC1ATRi, p-SCC2ATRi, and p-SCC3ATRi. B Oncoprint illustrating mutations predicted as “unclear” or “probably damaging” (indicated by asterisks) in key genes associated with BLCA [1, 58] and DNA repair pathways [76], as well as unique mutations identified exclusively in the resistant cell line following long-term culturing with allele frequency >0.1. Plot is stratified by sample origin (red: p-SCCATRi cell lines, light orange: parental p-SCC cell lines; dark orange: SCC tumor tissue). TMB (brown shades), gene alterations (grey shades), and pathway categories (green shades). C Circos plots depicting the copy number variation status of the three models across corresponding SCC tissue, parental cell line, and ATRi-resistant cell line. D TMB analysis revealed low status in each SCC tumor (dark orange, outer ring), the corresponding ex vivo cell line (light orange, middle ring), and the ATRi-resistant cell line (red, inner ring). Blue = deletion; red = amplification. E Summary of XTT cell viability assays showing a comparative shift in IC50 values for ATRi between parental (grey) and adapted (red) p-SCC models under 0 Gy, 2 Gy, and 8 Gy IR. Fold-changes in IC50 relative to the corresponding parental cultures are indicated, highlighting the development of resistance upon long-term ATR inhibition. F-H Functional validation of ATRi-adaptation in p-SCC1/p-SCC1ATRi, p-SCC2/p-SCC2ATRi, and p-SCC3/p-SCC3ATRi models. Top: XTT cell viability assays (72 h) under increasing concentrations of ATRi (0.01–20 µM), ± IR (0, 2, or 8 Gy). Bottom: Immunoblot analysis of total CHK1 and phosphorylated CHK1 at Ser317. Vinculin served as loading control. Protein level analysis and raw images of immunoblots are shown in Suppl. Fig. S6 (n = 1)
Supplier Page from OriGene Technologies for ATR Human siRNA Oligo Duplex (Locus ID 545)